Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)

Journal of Pathology

Volumn 220, Issue 5, 2010, Pages 586-595

  Sotlar, Karl ^a   Colak, Sema ^b   Bache, Anja ^b   Berezowska, Sabina ^a   Krokowski, Manuela ^c   Bültmann, Burkhard ^b   Valent, Peter ^e   Horny, Hans Peter ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Institute of Pathology   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone marrow; KITD816v; Mastocytosis; Microdissection; PNA; SM AHNMD; Tyrosine kinase inhibitors

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASSOCIATED CLONAL HAEMATOLOGICAL NON MAST CELL LINEAGE DISEASE; BONE MARROW; CANCER PATIENT; CELL LINEAGE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; EOSINOPHILIC LEUKEMIA; FEMALE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIT ONCOGENE; LASER MICRODISSECTION; LEUKEMIA CELL; MALE; MAST CELL; MELTING POINT; MOLECULAR CLONING; MUTANT; MYELOPROLIFERATIVE DISORDER; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; BLOOD DISEASE; CANCER STEM CELL; GENETICS; METHODOLOGY; MICRODISSECTION; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; RETROSPECTIVE STUDY; TRANSITION TEMPERATURE;

DNA; STEM CELL FACTOR RECEPTOR;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MICRODISSECTION; MIDDLE AGED; MUTATION; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; TRANSITION TEMPERATURE;

EID: 77949865698     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2677     Document Type: Article

References (46)

1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979;3:349-365.
2. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2-4S; discussion, 4S, 60-65S.
3. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:695-717.
4. Horny H-PMD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis (mast cell disease). In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al (eds). IARC Press: Geneva, 2008; 54-63.
5. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-972.
6. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002;127:140-142.
7. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-608.
8. Sanz MA, Valcarcel D, Sureda A, Munoz L, Espinosa I, Nomdedeu J, et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica 2001;86:1106-1107.
9. Horny HP, Sotlar K, Stellmacher F, Valent P, Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 2006;59:264-268.
10. Sotlar K, Saeger W, Stellmacher F, Stahmer J, Jackle S, Valent P, et al. 'Occult' mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol 2006;59:875-878.
11. Kim Y, Weiss LM, Chen YY, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res 2007;31:1749-1754.
12. Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8; 21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007;31:261-265.
13. Hauswirth AW, Fodinger M, Fritz M, Mullauer L, Simonitsch-Klupp I, Streubel B, et al. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Hum Pathol 2008;39:917-924.
14. Bernd HW, Sotlar K, Lorenzen J, Osieka R, Fabry U, Valent P, et al. Acute myeloid leukaemia with t(8; 21) associated with 'occult' mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004;57:324-328.
15. Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008;10:58-66.
16. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
17. Nagai S, Ichikawa M, Takahashi T, Sato H, Yokota H, Oshima K, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 2007;35:1747-1752.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
19. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325.
20. Sotlar K, Selinka HC, Menton M, Kandolf R, Bültmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998;69:114-121.
21. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737-746.
22. Schütze K, Lahr G. Identification of expressed genes by laser-mediated manipulation of single cells. Nat Biotechnol 1998;16:737-742.
23. Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990;76:186-193.
24. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-624.
25. Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 2004;121:264-267.
26. Johnson MR, Verstovsek S, Jorgensen JL, Manshouri T, Luthra R, Jones DM, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol 2009;22:50-57.
27. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001;25:553-562.
28. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200- 2209.
29. Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002;43:1097-1105.
30. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
31. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008;180:5466-5476.
32. Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007;120:680-687.
33. Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778-1785.
34. Agis H, Fureder W, Bankl HC, Kundi M, Sperr WR, Willheim M, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology 1996;87:535-543.
35. Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000;37:473-486.
36. Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M, et al. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13; 13)(q12; q22) involving FLT3. J Clin Pathol 2008;61:958-961.
37. Wong KF, Chan JK, Chan JC, Kwong YL, Ma SK, Chow TC. Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 1991;38:243-244.
38. Escribano L, Garca-Montero A, Nunez-Lopez R, Lopez-Jimenez J, Almeida J, Prados A, et al. Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. J Allergy Clin Immunol 2004;114:28-33.
39. Pullarkat VA, Bueso-Ramos C, Lai R, Kroft S, Wilson CS, Pullarkat ST, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73:12-17.
40. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661-665.
41. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol 2002;127:137-139.
42. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-521.
43. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-1744.
44. Cairoli R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L, et al. Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations. A report of three cases. Leuk Res 2005;29:397-400.
45. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
46. Bain BJ GD, Horny H-P, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB of FGFR1. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al (eds). IARC Press: Geneva, 2008; 68-73.